Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

VU0661013 is an inhibitor of myeloid cell leukemia-1 (Mcl-1; Ki = 97 pM).1 It is selective for Mcl-1 over Bcl-xL and Bcl-2 (Kis = >40 and 0.73 µM, respectively). VU0661013 inhibits cell growth in a panel of acute myeloid leukemia (AML) cell lines (GI50s = 0.16-7.62 µM). It decreases blood, bone marrow, and spleen leukemic burden, reduces splenomegaly, and increases survival in a MV4-11 disseminated AML mouse xenograft model when administered at a dose of 75 mg/kg. VU0661013 also selectively inhibits glutathione peroxidase 4 (GPX4; IC50 = 8.4 µM) over GPX1, GPX2, glutathione reductase (GR), and thioredoxin reductase 1 (TrxR1).2
WARNING This product is not for human or veterinary use.
1. A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-
2. Development of an assay pipeline for the discovery of novel small molecule inhibitors of human glutathione peroxidases GPX1 and GPX4. Redox Biol. 63:102719, (2023).